Victory Capital Management Inc. reduced its stake in Agilent Technologies, Inc. (NYSE:A - Free Report) by 3.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,295,817 shares of the medical research company's stock after selling 90,222 shares during the quarter. Victory Capital Management Inc. owned 0.80% of Agilent Technologies worth $340,883,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Agilent Technologies by 18.2% during the 1st quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company's stock worth $4,348,471,000 after buying an additional 4,605,228 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Agilent Technologies by 13.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company's stock worth $1,242,956,000 after purchasing an additional 1,042,926 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Agilent Technologies by 5.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company's stock valued at $1,952,832,000 after buying an additional 809,149 shares in the last quarter. Champlain Investment Partners LLC acquired a new position in shares of Agilent Technologies during the 1st quarter worth $61,218,000. Finally, Marshall Wace LLP grew its stake in Agilent Technologies by 48.6% in the 2nd quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company's stock valued at $124,073,000 after acquiring an additional 313,155 shares during the last quarter.
Agilent Technologies Stock Down 0.1 %
NYSE:A traded down $0.20 during mid-day trading on Tuesday, reaching $133.66. The stock had a trading volume of 1,490,442 shares, compared to its average volume of 1,704,506. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37. The company has a market capitalization of $38.40 billion, a price-to-earnings ratio of 27.77, a price-to-earnings-growth ratio of 6.01 and a beta of 1.07. Agilent Technologies, Inc. has a 1-year low of $106.96 and a 1-year high of $155.35. The stock's 50 day simple moving average is $139.27 and its two-hundred day simple moving average is $138.19.
Agilent Technologies (NYSE:A - Get Free Report) last issued its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping analysts' consensus estimates of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The company had revenue of $1.58 billion for the quarter, compared to analysts' expectations of $1.56 billion. During the same period in the prior year, the company earned $1.43 earnings per share. The firm's revenue was down 5.6% compared to the same quarter last year. Equities analysts anticipate that Agilent Technologies, Inc. will post 5.24 EPS for the current year.
Agilent Technologies Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were given a $0.236 dividend. This represents a $0.94 annualized dividend and a yield of 0.71%. The ex-dividend date was Tuesday, October 1st. Agilent Technologies's dividend payout ratio is currently 19.50%.
Insider Buying and Selling at Agilent Technologies
In related news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the transaction, the chief executive officer now owns 24,118 shares in the company, valued at $3,497,110. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the business's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm's stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the transaction, the chief executive officer now owns 24,118 shares of the company's stock, valued at approximately $3,497,110. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,995 shares of company stock valued at $1,739,510 in the last quarter.
Wall Street Analysts Forecast Growth
A has been the subject of a number of recent research reports. Barclays boosted their target price on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an "underweight" rating in a research note on Tuesday, October 15th. UBS Group upped their target price on Agilent Technologies from $141.00 to $150.00 and gave the company a "neutral" rating in a research note on Thursday, August 22nd. Stifel Nicolaus reissued a "buy" rating and issued a $151.00 price target on shares of Agilent Technologies in a research note on Monday, August 26th. TD Cowen upped their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a "buy" rating in a research note on Thursday, August 22nd. Finally, Bank of America boosted their price objective on shares of Agilent Technologies from $140.00 to $147.00 and gave the company a "neutral" rating in a research note on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Agilent Technologies currently has a consensus rating of "Moderate Buy" and a consensus price target of $144.36.
Check Out Our Latest Stock Analysis on Agilent Technologies
Agilent Technologies Profile
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Recommended Stories
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
